Low- versus standard-dose alteplase in acute lacunar ischemic stroke: the ENCHANTED trial - online supplemental
Authors/Creators
-
Zhou, Zien1
- Delcourt, Candice1
- Xia, Chao1
- Yoshimura, Sohei1
- Carcel, Cheryl1
- Torii-Yoshimura, Takako1
- You, Shoujiang2
- Malavera, Alejandra1
- Chen, Xiaoying1
- Hackett, Maree1
- Woodward, Mark1
- Chalmers, John1
- Xu, Jianrong3
- Robinson, Thompson4
- Parsons, Mark5
- Demchuk, Andrew6
- Lindley, Richard1
- Mair, Grant7
- Wardlaw, Joanna7
- Anderson, Craig1
- 1. George Institute for Global Health
- 2. Department of Neurology, the Second Affiliated Hospital of Soochow University, Suzhou, PR China.*
- 3. Shanghai Jiao Tong University
- 4. NIHR Leicester Cardiovascular Biomedical Research Unit
- 5. University of New South Wales
- 6. University of Calgary
- 7. University of Edinburgh
Description
Objective: To determine any differential efficacy and safety of low- versus standard-dose intravenous alteplase for lacunar versus non-lacunar acute ischemic stroke (AIS), we performed post-hoc analyzes from the Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) alteplase dose-arm.
Methods: In a cohort of 3297 ENCHANTED participants, we identified those with lacunar or non-lacunar AIS with different levels of confidence (definite/probable/possible) according to pre-specified definitions based on clinical and adjudicated imaging findings. Logistic regression models were used to determine associations of lacunar AIS with 90-day outcomes (primary, modified Rankin scale [mRS] scores 2-6; secondary, other mRS scores, intracerebral hemorrhage [ICH], and early neurologic deterioration [END] or death) and treatment effects of low- versus standard-dose alteplase across lacunar and non-lacunar AIS with adjustment for baseline covariables.
Results: Of 2588 participants with available imaging and clinical data, we classified cases as definite/probable lacunar (n=490) or non-lacunar AIS (n=2098) for primary analyses. Regardless of alteplase dose received, lacunar AIS participants had favorable functional (mRS 2-6, adjusted odds ratio [95% CI] 0.60 [0.47-0.77]) and other clinical or safety outcomes, compared to participants with non-lacunar AIS. Low-dose alteplase (versus standard) had no differential effect on functional outcomes (mRS 2-6, 1.04 [0.87-1.24]) but reduced the risk of symptomatic ICH in all included participants. There were no differential treatment effects of low- versus standard-dose alteplase on all outcomes across lacunar and non-lacunar AIS (all Pinteraction ≥0.07).
Conclusions: We found no evidence from the ENCHANTED trial that low-dose alteplase had any advantages over standard-dose for definite/probable lacunar AIS.
Notes
Funding provided by: The National Health and Medical Research Council (NHMRC) of Australia*
Crossref Funder Registry ID:
Award Number: 1020462 and 1101113
Funding provided by: The Stroke Association of the UK*
Crossref Funder Registry ID:
Award Number: TSA 2012/01 and 2015/01
Funding provided by: The Ministry of Health and the National Council for Scientific and Technological Development of Brazil *
Crossref Funder Registry ID:
Award Number: CNPQ: 467322/2014-7, 402388/2013-5
Funding provided by: The Ministry for Health, Welfare and Family Affairs of the Republic of Korea *
Crossref Funder Registry ID:
Award Number: HI14C1985
Funding provided by: A research grant from Takeda for conduct of the study in China*
Crossref Funder Registry ID:
Award Number: NA
Files
Files
(82.4 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:3be60608d161a24ab7628787b35d8b59
|
82.4 kB | Download |